Impact of Hypertonic Saline Solution on Acute Decompensated Heart Failure

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Acute decompensated heart failure (HF) is one of the most common cardiologic issues in emergency departments.

Loop diuretics have long been recognized as the key for the treatment of Acute Decompensated Heart Failure (ADHF).However, chronic treatment with diuretics may limit their response and deteriorates the renal function. The hypertonic saline solution (HSS) has been proposed in recent years as an adjunctive therapy for intravenous loop diuretics to improve or restore their initial pharmacological efficacy.

In this study the investigators will evaluate the effectiveness of HSS as an adjunct to i.v. furosemide in patients admitted for AHF with renal dysfunction

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Monastir

Criteria

Inclusion Criteria:

• Patients with 18 years of age or older

• ADHF with congestive symptoms, laboratory(BNP) and echocardiographic criteria

• NYHA ≥II(New York Heart Association functional classification)

• Creatinine clearance≤60ml/mn (MDRD) or level of creatinine >150 µg/ml)

• BNP levels on admission ≥400 pg/mL

Exclusion Criteria:

• age < 18 years

• NYHA class < II

• Patients with acute coronary syndrome, pulmonary thromboembolism, cardiac tamponade, pericarditis, those on dialysis; patients with chronic liver disease, pleuropneumonia, cerebral vascular disease, cancer, uncompensated diabetes, patients requiring pacemaker and concomitant other important comorbidity

• Signs of hemodynamic instability, respiratory distress, coma